Close Menu

Merck KGaA

AmoyDx aims to develop a companion diagnostic for Merck KGaA's non-small cell lung cancer treatment Tepmetko, which was recently approved in Japan.

Metabolon's Precision Metabolomics platform identifies pharmacodynamic, efficacy, and response biomarkers and tracks changes in biological pathways.

The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 14 skipping alterations.

The partners plan to employ Personalis' ImmunoID NeXT platform to investigate biomarkers of response and mechanisms of resistance to cancer therapies.

An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.

Archer will develop and pursue regulatory approval for a companion diagnostic that will help find patients who may benefit from one of Merck's drug candidates.

Merck will use Definiens' web-based collaboration software platform alongside Definiens' image-analysis technologies for biomarker quantification.

The German drugmaker plans to advance the NSCLC treatment in parallel with tissue-based and liquid biopsy companion assays that can identify best responders.

The reagents involved in the deal improve the specificity and fidelity of PCR reactions.

The two companies have signed a new master collaboration agreement under which HTG will  develop custom assays for use in earlier stages of Merck's drug development process.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.